Dose adjustments of oncolytic drugs, including Jakafi, are often required to achieve maximum efficacy while managing toxicity. As a pharmacist, you play an integral role in the management of oral oncolytics. For this reason, Incyte has developed the following resources to assist you with dose optimization of Jakafi for appropriate patients with intermediate- or high-risk myelofibrosis.
Utilizing a pharmacy dosing initiative and providing your unique perspective to your colleagues on the care team can help support appropriate care for this patient population practice-wide. Learn more about implementing a pharmacy dosing initiative for Jakafi with the materials below.
“Careful patient monitoring and appropriate [Jakafi] dose titration
as needed is an effective approach to optimizing treatment.”
(Verstovsek S et al. Onco Targets Ther. 2014;7:13-21.)